Evogene Ltd (NASDAQ:EVGN) was the recipient of a significant decrease in short interest in January. As of January 31st, there was short interest totalling 29,900 shares, a decrease of 26.7% from the January 15th total of 40,800 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average trading volume of 10,100 shares, the days-to-cover ratio is presently 3.0 days.
A hedge fund recently raised its stake in Evogene stock. ARK Investment Management LLC boosted its holdings in Evogene Ltd (NASDAQ:EVGN) by 8.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 227,211 shares of the biotechnology company’s stock after acquiring an additional 17,963 shares during the quarter. ARK Investment Management LLC owned about 0.88% of Evogene worth $345,000 as of its most recent filing with the SEC. 29.21% of the stock is owned by institutional investors and hedge funds.
NASDAQ:EVGN remained flat at $$1.51 during trading hours on Friday. The company’s stock had a trading volume of 26,100 shares, compared to its average volume of 20,053. The company has a 50-day moving average price of $1.61 and a 200-day moving average price of $1.56. The firm has a market capitalization of $38.89 million, a P/E ratio of -2.16 and a beta of 1.22. The company has a debt-to-equity ratio of 0.03, a current ratio of 11.38 and a quick ratio of 11.38. Evogene has a 1 year low of $1.26 and a 1 year high of $2.65.
Evogene Ltd., a biotechnology company, engages in developing various products for various life science markets through the use of computational predictive biology platform in the United States, Germany, and internationally. It discovers and develops products in various areas, including ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions, and human microbiome-based therapeutics.
Read More: How do candlesticks reflect price movement?
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.